PedAM
Pediatric Disease Annotations & Medicines
| Disease | thromboembolism |
| Phenotype | C0026764|multiple myeloma |
| Sentences | 14 |
| PubMedID- 20874693 | The background rate of thromboembolism is 4-11% in patients with multiple myeloma, which increases to 15-20% in patients who received intensive treatment with thalidomide. |
| PubMedID- 21859556 | Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. |
| PubMedID- 19901114 | Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. |
| PubMedID- 21720994 | Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. |
| PubMedID- 26177588 | Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide. |
| PubMedID- 24599441 | Venous thromboembolism in multiple myeloma. |
| PubMedID- 23903204 | Melisse, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. |
| PubMedID- 22511493 | We found multiple myeloma patients with venous thromboembolism to have a higher mortality at 1-, 5-, and 10-years of follow up compared with those without, with hazard ratios of 2.9 (95% confidence interval (ci) 2.4-3.5), 1.6 (95% ci: 1.5-1.8), and 1.6 (95% ci: 1.4-1.7), respectively. |
| PubMedID- 21255254 | Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. |
| PubMedID- 23014188 | Purpose of review: this review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (vte) in patients with lymphoma, multiple myeloma or acute leukemia. |
| PubMedID- 25632017 | This study identified the need for increased adherence to national guidelines for venous thromboembolism prevention in patients with multiple myeloma receiving immunomodulatory drug therapy so as to increase the quality of care provided at uc health. |
| PubMedID- 20385482 | Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. |
| PubMedID- 24151508 | Several different mechanisms have been described as possible causative factors for venous thromboembolic disease in patients with multiple myeloma. |
| PubMedID- 26432650 | This study focused on the clinical outcomes in multiple myeloma (mm) patients with venous thromboembolism (vte) who received low-molecular-weight heparin (dalteparin) therapy. |
Page: 1